Recombinant Human Coagulation Factor VIII – CRI Report https://www.cri-report.com market research vender! Fri, 29 Oct 2021 02:27:45 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg Recombinant Human Coagulation Factor VIII – CRI Report https://www.cri-report.com 32 32 Sample of Investigation Report on Recombinant Human Coagulation Factor VIII in China, 2018-2022 https://www.cri-report.com/sample-of-investigation-report-on-recombinant-human-coagulation-factor-viii-in-china-2018-2022/ Fri, 04 Jan 2019 06:44:18 +0000 https://www.cri-report.com/?post_type=product&p=6816 This is a free sample of Investigation Report on Recombinant Human Coagulation Factor VIII in China, 2018-2022

The post Sample of Investigation Report on Recombinant Human Coagulation Factor VIII in China, 2018-2022 first appeared on CRI Report.

]]> This is a free sample of

Investigation Report on Recombinant Human Coagulation Factor VIII in China, 2018-2022

The post Sample of Investigation Report on Recombinant Human Coagulation Factor VIII in China, 2018-2022 first appeared on CRI Report.

]]> Investigation Report on Recombinant Human Coagulation Factor VIII in China, 2018-2022 https://www.cri-report.com/investigation-report-on-recombinant-human-coagulation-factor-viii-in-china-2018-2022/ Fri, 17 Aug 2018 09:05:10 +0000 https://www.cri-report.com/product/import-placeholder-for-1806296/ Currently, recombinant human coagulation factor VIII sold on the Chinese market is all imported from Bayer, Baxalta and Wyeth. Bayer secures the highest market share, which was close to 68% in 2017.

The post Investigation Report on Recombinant Human Coagulation Factor VIII in China, 2018-2022 first appeared on CRI Report.

]]> There are more than 400,000 people with hemophilia in the world, Chinese surpassing 100,000. The registered hemophilia patients in China are less than 20,000, because most patients give up treatment due to the expensive medical expenses. Those who lack coagulation factor VIII account for 80% to 85% of the hemophilia A patients. Currently, there is no cure for hemophilia, treatment for which on the market are all alternatives. Coagulation factors are the main drugs.
In 1992, Baxter (Baxalta) publicized the first recombinant coagulation factor VIII. Because it has the same effects as natural coagulation factors without risks of blood-borne virus contamination, it is very popular in the market. The developed countries master mature technologies of recombinant coagulation factors. For example, recombinant coagulation factor VIII now has experienced four rounds of upgradation. The main manufacturers are Bayer, Baxalta, Wyeth, etc. By Jun. 2018, no domestic recombinant coagulation factor VIII has been launched. In May 2018, China’s local biopharmaceutical company Beijing Tiantan Biological Products Co., Ltd. announced that its subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd. had received Approval Document for Clinical Trials of recombinant human coagulation factor VIII for injection issued by the CFDA.
Recombinant human coagulation factor VIII developed rapidly after entering China. Its annual sales increased from less than CNY 6 million in 2009 to CNY 300 million in 2017, and the CAGR reached 65.2% from 2009 to 2017. Currently, recombinant human coagulation factor VIII sold on the Chinese market is all imported from Bayer, Baxalta and Wyeth. Bayer secures the highest market share, which was close to 68% in 2017.
CRI forecasts that with the development of China’s economy, patients with hemophilia are more able to pay medical expenses. It is expected that the market scale of recombinant human coagulation factor VIII in China will continue to increase from 2018 to 2022. After 2022, there is possibility that Chinese companies may launch recombinant human coagulation factor VIII.

Topics Covered
Development of Recombinant Human Coagulation Factor VIII in China
Sales of Recombinant Human Coagulation Factor VIII in China
Sale price of Recombinant Human Coagulation Factor VIII in the Chinese market
Manufacturers of Recombinant Human Coagulation Factor VIII in the Chinese market
Research progress of Chinese companies on Recombinant Human Coagulation Factor VIII
Chinese market prospects on Recombinant Human Coagulation Factor VIII from 2018 to 2022

 

The post Investigation Report on Recombinant Human Coagulation Factor VIII in China, 2018-2022 first appeared on CRI Report.

]]>